Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LRY015
MIFTS: 46

Laryngeal Benign Neoplasm

Categories: Cancer diseases, Oral diseases, Respiratory diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Laryngeal Benign Neoplasm

About this section

MalaCards integrated aliases for Laryngeal Benign Neoplasm:

Name: Laryngeal Benign Neoplasm 11 14
Laryngeal Carcinoma 33
Neoplasm of Larynx 11
Cancer of Larynx 33
Laryngeal Cancer 33
Laryngeal Tumor 11
Larynx Neoplasm 11

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Oral diseases
See all MalaCards categories (disease lists)
ICD11: 33


External Ids:

Disease Ontology 11 DOID:2598
MeSH 43 D007822
NCIt 49 C3156
SNOMED-CT 68 126692004
UMLS 71 C0023055
Sources

Summaries for Laryngeal Benign Neoplasm

About this section

MalaCards based summary: Laryngeal Benign Neoplasm, also known as laryngeal carcinoma, is related to larynx squamous papilloma and subglottis benign neoplasm. An important gene associated with Laryngeal Benign Neoplasm is MIR425 (MicroRNA 425), and among its related pathways/superpathways are Endometrial cancer and Breast cancer pathway. The drugs Nicotinamide and Cefazolin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, endothelial and thyroid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased cell death in HCT116 cells
Sources

Related Diseases for Laryngeal Benign Neoplasm

About this section

Diseases related to Laryngeal Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 621)
# Related Disease Score Top Affiliating Genes
1 larynx squamous papilloma 32.2 TP53 CDKN2A
2 subglottis benign neoplasm 31.9 PDPN NSD2 NSD1 CAGE1
3 larynx cancer 30.5 TP53 MIR106B EGFR CCND1
4 suppressor of tumorigenicity 3 30.5 TP53 CDKN2A
5 supraglottis cancer 30.5 PDPN CAGE1
6 epiglottis cancer 30.4 PDPN CAGE1
7 keratoacanthoma 30.2 TP53 PIK3CA EGFR CD44
8 laryngeal disease 30.1 MIR425 MIR133A1 MIR106B
9 papilloma 30.1 TP53 EGFR CDKN2A CCND1
10 head and neck cancer 30.0 TP53 PIK3CA MIR425 MIR133A1 MIR106B EGFR
11 oropharynx cancer 30.0 TP53 PIK3CA EGFR CDKN2A CCND1
12 peritoneal mesothelioma 30.0 TP53 PDPN CDKN2A
13 tongue carcinoma 30.0 TP53 EGFR CDKN2A CCND1
14 carcinosarcoma 30.0 TP53 PIK3CA EGFR CDKN2A
15 small cell cancer of the lung 30.0 TP53 PIK3CA EGFR CDKN2A
16 inverted papilloma 30.0 TP53 CDKN2A CCND1
17 lung benign neoplasm 30.0 TP53 EGFR CDKN2A
18 skin carcinoma 29.9 TP53 EGFR CDKN2A CCND1
19 spinal cord disease 29.9 TP53 MIR106B EGFR CDKN2A
20 esophagus adenocarcinoma 29.8 TP53 EGFR CDKN2A CCND1
21 skin squamous cell carcinoma 29.8 TP53 EGFR CDKN2A CCND1
22 verrucous carcinoma 29.8 TP53 PIK3CA PDPN EGFR CDKN2A
23 leiomyosarcoma 29.8 TP53 CDKN2A CCND1
24 pleomorphic carcinoma 29.8 TP53 EGFR
25 keratinizing squamous cell carcinoma 29.8 TP53 PIK3CA EGFR CDKN2A
26 keratosis 29.7 TP53 PIK3CA EGFR CDKN2A
27 laryngeal squamous cell carcinoma 29.7 TP53 EGFR CDKN2A CD44 CCND1
28 colon adenocarcinoma 29.6 TP53 PIK3CA EGFR CCND1
29 lung squamous cell carcinoma 29.6 TP53 PIK3CA NSD1 EGFR CDKN2A
30 supraglottis neoplasm 29.6 PDZK1IP1 PDPN CDKN2A CAGE1 BMI1
31 nasopharyngeal carcinoma 29.6 TP53 PIK3CA EGFR CDKN2A CD44 CCND1
32 lip and oral cavity cancer 29.6 TP53 PIK3CA EGFR CDKN2A CCND1
33 adenocarcinoma 29.6 TP53 PIK3CA EGFR CDKN2A CCND1
34 human papillomavirus infectious disease 29.6 TP53 PIK3CA EGFR CDKN2A CCND1
35 thyroid gland anaplastic carcinoma 29.6 TP53 PIK3CA MIR183 EGFR CCND1
36 lynch syndrome 29.5 TP53 PIK3CA EGFR CDKN2A CCND1
37 adenoid cystic carcinoma 29.5 TP53 PIK3CA EGFR CDKN2A CCND1
38 pancreatic adenocarcinoma 29.5 TP53 PIK3CA EGFR CDKN2A CCND1
39 wilms tumor 1 29.5 TP53 EGFR CDKN2A CD44 CCND1
40 lung cancer susceptibility 3 29.5 TP53 PIK3CA MIR183 MIR106B EGFR CDKN2A
41 cervical cancer 29.5 TP53 PIK3CA MIR106B CDKN2A CD44 CCND1
42 hypopharynx cancer 29.5 TP53 PDPN EGFR CDKN2A CCND1 CAGE1
43 hemangioma 29.5 TP53 PROM1 PDPN EGFR CDKN2A
44 adenoma 29.4 TP53 PIK3CA CDKN2A CD44 CCND1
45 b-cell lymphoma 29.4 TP53 CDKN2A CD44 CCND1 BMI1
46 peripheral nervous system disease 29.4 TP53 EGFR CDKN2A CD44 CCND1
47 kidney cancer 29.3 TP53 PIK3CA MIR106B EGFR CDKN2A CD44
48 squamous cell carcinoma 29.3 TP53 PIK3CA PDPN EGFR CDKN2A CD44
49 cholangiocarcinoma 29.2 TP53 PIK3CA EGFR CDKN2A CD44 CCND1
50 leukemia, chronic lymphocytic 29.2 TP53 MIR183 MIR106B EGFR CDKN2A CD44

Graphical network of the top 20 diseases related to Laryngeal Benign Neoplasm:



Diseases related to Laryngeal Benign Neoplasm
Sources

Symptoms & Phenotypes for Laryngeal Benign Neoplasm

About this section

GenomeRNAi Phenotypes related to Laryngeal Benign Neoplasm according to GeneCards Suite gene sharing:

25 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.66 BMI1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.66 TP53
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.66 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.66 EGFR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.66 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.66 TP53
7 Increased shRNA abundance (Z-score > 2) GR00366-A-184 9.66 TP53
8 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.66 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.66 BMI1 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-20 9.66 TP53
11 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.66 EGFR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.66 EGFR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.66 BMI1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.66 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.66 TP53
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.66 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.66 PIK3CA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-62 9.66 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.66 BMI1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.66 EGFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.66 EGFR
22 Increased cell death in HCT116 cells GR00103-A-0 8.96 BMI1 PIK3CA

MGI Mouse Phenotypes related to Laryngeal Benign Neoplasm:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.91 BMI1 CCND1 CD44 CDKN2A EGFR PIK3CA
2 no phenotypic analysis MP:0003012 9.7 CDKN2A EGFR NSD1 PIK3CA PROM1 TP53
3 digestive/alimentary MP:0005381 9.61 BMI1 CCND1 CD44 CDKN2A EGFR NSD2
4 cardiovascular system MP:0005385 9.36 BMI1 CCND1 CD44 CDKN2A EGFR MIR133A1
Sources

Drugs & Therapeutics for Laryngeal Benign Neoplasm

About this section

Drugs for Laryngeal Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
2
Cefazolin Approved Phase 3 25953-19-9 33255
3
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 5702198 441203
4
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
5
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
6
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
7
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
8
Sucralfate Approved Phase 3 54182-58-0
9
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
10
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
11 Vitamin B3 Phase 3
12 Nicotinic Acids Phase 3
13 Anti-Bacterial Agents Phase 3
14 Anti-Infective Agents Phase 3
15 Antimitotic Agents Phase 2, Phase 3
16 Tubulin Modulators Phase 2, Phase 3
17 Angiogenesis Inhibitors Phase 2, Phase 3
18 Endothelial Growth Factors Phase 2, Phase 3
19 Mitogens Phase 2, Phase 3
20 Aloe Phase 3
21 Anti-Ulcer Agents Phase 3
22 Antacids Phase 3
23 Gastrointestinal Agents Phase 3
24 Antineoplastic Agents, Immunological Phase 2, Phase 3
25 Immunologic Factors Phase 2, Phase 3
26 Immunoglobulins, Intravenous Phase 2, Phase 3
27 Immunoglobulins Phase 2, Phase 3
28 Immunoglobulin G Phase 2, Phase 3
29 Antibodies, Monoclonal Phase 2, Phase 3
30 Antibodies Phase 2, Phase 3
31 Raspberry Approved Phase 1, Phase 2
32
Hyaluronic acid Approved, Vet_approved Phase 2 9004-61-9 53477741
33
Sargramostim Approved, Investigational Phase 2 123774-72-1
34
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
35
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
36
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
37
Nivolumab Approved Phase 2 946414-94-4
38
Doxepin Approved, Investigational Phase 2 1668-19-5 667468 667477
39
Histamine Approved, Investigational Phase 2 51-45-6 774
40
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
41
Promethazine Approved, Investigational Phase 2 60-87-7 4927
42
Cetuximab Approved Phase 2 205923-56-4
43
Fluorouracil Approved Phase 2 51-21-8 3385
44
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
45
Arginine Approved, Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
46
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
47
Etanidazole Investigational Phase 2 22668-01-5 3276
48
(-)-Gossypol Investigational Phase 2 303-45-7, 90141-22-3 3503
49
Molgramostim Investigational Phase 2 99283-10-0
50
Pyrazole Experimental Phase 2 288-13-1

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy Unknown status NCT00497588 Phase 3
2 A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma. Completed NCT00147732 Phase 3
3 Double Blind Randomised Study of 2 Days and 5 Days Cefazolin Prophylactic Method in Laryngeal Oncologic Surgery Completed NCT00467948 Phase 3 cefazolin
4 A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers Recruiting NCT05063552 Phase 2, Phase 3 Carboplatin;Cisplatin;Docetaxel
5 Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis: a Single-blind Randomized Controlled Trial Recruiting NCT05369234 Phase 3 Carafate
6 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Active, not recruiting NCT03258554 Phase 2, Phase 3
7 Phase II Organ Preservation Trial Using Cisplatin Concomitant With Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to Induction Chemotherapy With Taxotere, Cisplatin, and 5-Fluorouracil (TPF) Unknown status NCT01073683 Phase 2 Taxotere (Docetaxel), Cisplatin, 5FU
8 Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer Completed NCT00827164 Phase 2
9 Clinical Outcomes Modeling for Laryngectomy Surgery Patients and Efficacy of Hyperbaric Oxygen Therapy Completed NCT00026975 Phase 2
10 Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer Completed NCT01633541 Phase 2 AT-101;Docetaxel;Cisplatin;Carboplatin
11 Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer Completed NCT02849314 Phase 1, Phase 2
12 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
13 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention
14 Injection Thyroplasty During Transoral Laser Microsurgery for Early Glottic Cancer: Single-blinded Randomized Controlled Trial Completed NCT04525066 Phase 2 Hyaluronic acid
15 A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab Completed NCT01435252 Phase 2 Cetuximab
16 Randomised Phase II Study of GM-CSF to Reduce Severity of Mucositis Caused by Accelerated Radiotherapy of Laryngeal Cancer Completed NCT00004256 Phase 2
17 RESILIENCE: Effect of Comprehensive Celecoxib Through Treatment for Advanced-Stage Head and Neck Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial Recruiting NCT04162873 Phase 2 Celecoxib
18 Hypofractionated Proton Therapy for the Treatment of Head and Neck Cancer, The HEADLIGHT Study" Recruiting NCT05075980 Phase 2 Cisplatin
19 Intensifying Radiation Treatment in Advanced/ Poor Prognosis Laryngeal, Hypopharyngeal (LH) and Oropharyngeal Cancers (OPC) Using PET -CT Based Dose Escalation Strategies ( INTELHOPE) Recruiting NCT02757222 Phase 1, Phase 2
20 A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Recruiting NCT05172258 Phase 2 Ipatasertib
21 A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting NCT04862650 Phase 2 Carboplatin;Paclitaxel
22 Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing Recruiting NCT02734537 Phase 2 Cisplatin
23 Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP) Recruiting NCT04030455 Phase 2 Carboplatin;Cisplatin;Docetaxel
24 Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study Recruiting NCT05136196 Phase 2 Cabozantinib S-malate
25 Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma Recruiting NCT04995120 Phase 2 chemotherapy TP regimen combined with Toripalimab
26 Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma Recruiting NCT05420597 Phase 2 Toripalimab
27 A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin Active, not recruiting NCT04541355 Phase 2 Cisplatin;Sodium Thiosulfate
28 A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy Terminated NCT02062632 Phase 2 Doxepin Hydrochloride
29 A Phase II Organ Preservation Trial Using Cetuximab and Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to One Cycle of Induction Chemotherapy With Taxotere, Cisplatin, 5-Fluorouracil (TPF), and Cetuximab Terminated NCT00599131 Phase 2 Cisplatin;Cetuximab;5-Fluorouracil;Docetaxel
30 Induction Chemotherapy With TPF Followed by Radioimmunotherapy With Cetuximab and Intensity Modulated Radiotherapy (IMRT) Plus Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypopharynx and Larynx: TPF-C-HIT Terminated NCT01245985 Phase 2
31 Resistance Training and Physical Functioning in Head and Neck Cancer Patients Completed NCT01332682 Phase 1
32 Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer Completed NCT01445405 Phase 1 Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin
33 Phase I/Ib Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer Recruiting NCT05172245 Phase 1 Cisplatin;Ipatasertib
34 Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma Recruiting NCT04576091 Phase 1 Elimusertib
35 Proton Image-Guided Radiation Assignment for Therapeutic Escalation Via Selection of Locally Advanced Head and Neck Cancer Patients [PIRATES] Recruiting NCT04870840 Phase 1
36 Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma Active, not recruiting NCT02229656 Phase 1 Olaparib
37 Phase Ib Study of Pembrolizumab in Combination With Chemo Radiotherapy (CRT) for Locally-advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Active, not recruiting NCT02586207 Phase 1 pembrolizumab (MK-3475);Cisplatin
38 A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer Active, not recruiting NCT03114462 Phase 1
39 Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Suspended NCT04533750 Phase 1 Peposertib
40 A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer Terminated NCT02464137 Phase 1
41 A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Selective Neck Dissection for Clinically Negative Neck of Supraglottic Laryngeal Carcinoma Unknown status NCT03392220
42 Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma Unknown status NCT01171235
43 Effect of Perioperative ERAS Based Nursing Intervention on Hope Level of Patients With Laryngeal Cancer Unknown status NCT04174950
44 A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients Unknown status NCT03039465
45 Development and Validation of Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer: a Single-institutional Study Unknown status NCT03747783
46 Development and Validation of Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer: a Single-institutional Study Unknown status NCT03595410
47 The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Unknown status NCT00174096
48 The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Unknown status NCT00173381
49 The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Unknown status NCT00302562
50 Thulium Contact Laser in the Treatment of Tumorous and Non-tumorous Laryngotracheal Stenosis Completed NCT02587546

Search NIH Clinical Center for Laryngeal Benign Neoplasm

Sources

Genetic Tests for Laryngeal Benign Neoplasm

About this section
Sources

Anatomical Context for Laryngeal Benign Neoplasm

About this section

Organs/tissues related to Laryngeal Benign Neoplasm:

MalaCards : Lymph Node, Endothelial, Thyroid, Lung, Trachea, Neutrophil, Tongue
Sources

Publications for Laryngeal Benign Neoplasm

About this section

Articles related to Laryngeal Benign Neoplasm:

(show top 50) (show all 9262)
# Title Authors PMID Year
1
Convulsive Syncope From Carotid Sinus Syndrome as a Manifestation of Laryngeal Cancer. 62
35130751 2023
2
Management of double carotid blowout with definitive repair after temporizing stent graft placement. 62
36248383 2022
3
Epidemiological, clinical and oncological outcomes of young patients with laryngeal cancer: a systematic review. 62
35652941 2022
4
Vocal fold fibroblasts promote angiogenesis in vocal fold leukoplakia by secreting pro-angiogenic factors. 62
35513993 2022
5
Corrigendum to "Anterolateral thigh free flap reconstruction of pharyngoesophageal defect caused by radiotherapy for laryngeal cancer: A case report" [Oral Oncol. 134 (2022) 106135]. 62
36344370 2022
6
Fibroblast-epithelial metabolic coupling in laryngeal cancer. 62
36327815 2022
7
Controlling Nutritional Status (CONUT) score is a prognostic marker for laryngeal cancer patients with curative resection. 62
36169119 2022
8
Letter to the editor "prognostic scores in laryngeal cancer". 62
35253082 2022
9
Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability. 62
36471398 2022
10
Functional Outcomes Following Total Laryngectomy and Pharyngolaryngectomy: A 20-Year Single Center Study. 62
35081778 2022
11
150 years ago: First complete removal of the larynx by Theodor Billroth. 62
36333211 2022
12
Factors predicting pharyngocutaneous fistula in patients after salvage laryngectomy for laryngeal malignancy - A multicenter collaborative cohort study. 62
36057225 2022
13
Intake of prebiotic fibers and the risk of laryngeal cancer: the PrebiotiCa study. 62
36335543 2022
14
Non-Targeted Serum Lipidomics Analysis and Potential Biomarkers of Laryngeal Cancer Based on UHPLC-QTOF-MS. 62
36355170 2022
15
An Improvised Deep-Learning-Based Mask R-CNN Model for Laryngeal Cancer Detection Using CT Images. 62
36433430 2022
16
Causes of death after laryngeal cancer diagnosis: A US population-based study. 62
36357608 2022
17
Anterolateral thigh free flap reconstruction of pharyngoesophageal defect caused by radiotherapy for laryngeal cancer: A case report. 62
36166929 2022
18
Selective local postoperative radiotherapy for T3-T4 N0 laryngeal cancer. 62
36074137 2022
19
The global, regional, national burden of laryngeal cancer and its attributable risk factors (1990-2019) and predictions to 2035. 62
35980023 2022
20
Construction of a 10-gene prognostic score model of predicting recurrence for laryngeal cancer. 62
36376905 2022
21
Potential ferroptosis-related diagnostic and prognostic biomarkers in laryngeal cancer. 62
35829804 2022
22
THBS1, a fatty acid-related metabolic gene, can promote the development of laryngeal cancer. 62
36335208 2022
23
The efficacy and safety of radiotherapy combined chemotherapy for laryngeal preservation in advanced laryngeal cancer: A protocol for systematic review and meta-analysis. 62
36401448 2022
24
Loss of exosomal miR-34c-5p in cancer-associated fibroblast for the maintenance of stem-like phenotypes of laryngeal cancer cells. 62
35866307 2022
25
HAGLROS knockdown restrained cell proliferation, migration and invasion and facilitated apoptosis in laryngeal cancer via miR-138-5p/CLN5 axis. 62
36347825 2022
26
Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019. 62
35930449 2022
27
LncRNA ZFAS1 promotes laryngeal cancer progression through RBFOX2-mediated MENA alternative splicing. 62
36336961 2022
28
A review on the role of miR-210 in human disorders. 62
36446306 2022
29
Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival. 62
36173618 2022
30
[Clinical analysis of 12 cases of laryngeal neuroendocrine carcinoma]. 62
36404660 2022
31
[A case of Madelung's disease combined with laryngeal cancer]. 62
36347584 2022
32
CO2-TOLMS for laryngeal cancer in the elderly, pushing the boundaries of partial laryngectomy. 62
36087502 2022
33
Elemental Analysis of Laryngeal Cancer Patients in Comparison with Controls Using Scalp Hair as an Analytical Tool. 62
36355263 2022
34
The prognostic value of tumor mutational burden related 6-gene-based Risk Score in laryngeal cancer patients. 62
36397112 2022
35
Application of difficult endotracheal intubation under fluoroscopy in otorhinolaryngology head and neck surgery. 62
35635650 2022
36
Lysyl Oxidase Like-4 (LOXL4) as a tumor marker and prognosticator in advanced stage laryngeal cancer. 62
33757755 2022
37
Investigation of imbalances in essential/toxic metal levels in the blood of laryngeal cancer patients in comparison with controls. 62
36370262 2022
38
Elective neck dissection for T3-T4N0 laryngeal carcinoma: evidence from Japan's National Head and Neck Cancer Registry. 62
36436179 2022
39
Trends in Incidence and Mortality of Larynx Cancer in the US. 62
36394832 2022
40
Factors Influencing Postoperative Prognosis in Patients with Hypopharyngeal and Laryngeal Carcinoma. 62
36427261 2022
41
Association Between Alcohol Dehydrogenase Polymorphisms and the Recurrence of Laryngeal Carcinoma. 62
35218021 2022
42
Multidimensional Voice Assessment After Management of Early Laryngeal Cancer: A Comparative Study. 62
36466193 2022
43
Deriving prognostic significance from a molecular subtype model of laryngeal carcinoma. 62
35809031 2022
44
Occult lymph node metastasis in patients with laryngeal cancer and relevant predicting factors: a single-center experience. 62
34192979 2022
45
Preparation and inhibitory effect of salicin dimethyl ether in Laryngeal cancer cells through the apoptosis activation. 62
36269869 2022
46
Global microRNA expression profile in laryngeal carcinoma unveils new prognostic biomarkers and novel insights into field cancerization. 62
36224266 2022
47
Nerolidol assists Cisplatin to induce early apoptosis in human laryngeal carcinoma Hep 2 cells through ROS and mitochondrial-mediated pathway: An in vitro and in silico view. 62
36226832 2022
48
Clinical and experimental study of a terahertz time-domain system for the determination of the pathological margins of laryngeal carcinoma. 62
36224600 2022
49
Effect of transoral laser microsurgery vs open partial laryngectomy on the prognosis of patients with early laryngeal carcinoma: propensity score-based analysis. 62
36239784 2022
50
Conformity between modified Swallowing Outcome After Laryngectomy questionnaire and Flexible Endoscopic Evaluation of Swallowing in laryngeal carcinoma patients after total laryngectomy. 62
36310823 2022
Sources

Variations for Laryngeal Benign Neoplasm

About this section
Sources

Expression for Laryngeal Benign Neoplasm

About this section
Search GEO for disease gene expression data for Laryngeal Benign Neoplasm.
Sources

Pathways for Laryngeal Benign Neoplasm

About this section

Pathways related to Laryngeal Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 74
Show member pathways
 12.45 CCND1 CDKN2A EGFR PIK3CA TP53
2
Breast cancer pathway 74
Show member pathways
 12.29 TP53 PIK3CA EGFR CCND1
3
Malignant pleural mesothelioma 74
12.11 TP53 PIK3CA EGFR CDKN2A CD44 CCND1
4
MAPK Signaling: Mitogens 65
Show member pathways
 12.06 TP53 PIK3CA EGFR CCND1
5
T-cell activation SARS-CoV-2 74
Show member pathways
 11.85 TP53 PIK3CA CDKN2A CCND1
6
DNA damage response (only ATM dependent) 74
11.78 TP53 PIK3CA CCND1
7
Small cell lung cancer 74
11.74 TP53 PIK3CA CCND1
8
Hippo-Merlin signaling dysregulation 74
Show member pathways
 11.7 EGFR CD44 CCND1
9
Senescence and autophagy in cancer 74
11.64 TP53 CDKN2A CD44 BMI1
10
Neural Stem Cells and Lineage-specific Markers 65
11.61 PROM1 CD44 BMI1
11
Gastrin signaling pathway 74
11.6 PIK3CA EGFR CDKN2A CD44 CCND1
12
AP-1 transcription factor network 61
11.54 TP53 CDKN2A CCND1
13
miRNAs involved in DNA damage response 74
11.51 TP53 MIR106B CCND1
14
Pathways affected in adenoid cystic carcinoma 74
11.46 TP53 PIK3CA NSD1
15
Prader-Willi and Angelman syndrome 74
11.43 TP53 CDKN2A CCND1
16
Copper homeostasis 74
Show member pathways
 11.4 TP53 PIK3CA CCND1
17
Hepatitis C and hepatocellular carcinoma 74
11.32 TP53 CD44 CCND1
18
Bladder cancer 74
11.16 TP53 EGFR CDKN2A CCND1
19
Head and neck squamous cell carcinoma 74
10.88 TP53 PIK3CA EGFR CDKN2A CCND1
20
Relationship between inflammation, COX-2 and EGFR 74
10.55 PIK3CA EGFR
Sources

GO Terms for Laryngeal Benign Neoplasm

About this section

Biological processes related to Laryngeal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of lamellipodium morphogenesis GO:2000392 9.26 PDPN CD44
2 positive regulation of miRNA maturation GO:1903800 9.16 TP53 EGFR
3 response to UV-A GO:0070141 8.92 EGFR CCND1

Molecular functions related to Laryngeal Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone H4K20 methyltransferase activity GO:0042799 9.26 NSD2 NSD1
2 mRNA base-pairing translational repressor activity GO:1903231 9.02 MIR425 MIR183 MIR133A1 MIR106B
Sources

Sources for Laryngeal Benign Neoplasm

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....